PećinIHartgersMLHovinghGK, et al.Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol2017; 24: 1383–1401.
2.
AIFA (Italian Medicines Agency). Gazzetta Ufficiale n.31 del 07 febbraio 2017. Classificazione del medicinale per uso umano «Repatha», ai sensi dell'art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 172/2017) (17A01047), 2017.
3.
AIFA (Italian Medicines Agency). Gazzetta Ufficiale n.24 del 06 marzo 2017. Classificazione del medicinale per uso umano «Praluent» ai sensi dell'art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 256/2017) (17A01583). 2017.
4.
Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. Epub ahead of print 31 August 2019. DOI: 10.1093/eurheartj/ehz455.
5.
SbranaFDal PinoBBigazziF, et al.HeFH in real life, how to: More evolocumab than authorized. Eur J Prev Cardiol.. 2020; 27: 2079–2080.
6.
LeibowitzMKarpatiTCohen-StaviCJ, et al.Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Int Med2016; 176: 1105–1113.
7.
SampietroTBigazziFSbranaF, et al.Personalized regimen for PCSK9 inhibitors: A therapeutic option that maintains efficacy and reduces costs. J Clin Lipidol2018; 12: 1324–1325.
8.
SbranaFDal PinoBBigazziF, et al.Statin intolerance in heterozygous familial hypercholesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?. Eur J Prev Cardiol2017; 24: 1528–1531.
9.
SpitthöverRRöselerTJuliusU, et al.Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. J Clin Apher2019; 34: 423–433.
10.
SbranaFBigazziFDal PinoB, et al.Elusive therapeutic effect of PCSK9 inhibitors on lipoprotein(a) levels. Ther Apher Dial2019; 23: 385–386.
11.
RuscicaMWattsGFSirtoriCR. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): Making choices in an era of RNA-based therapies. Eur J Prev Cardiol2019; 26: 998–1000.
